Only 0.3% of FDA-cleared radiology AI devices have registered trials on patient outcomes, raising concerns about evidence standards.
Key Details
- 11,059 FDA-cleared AI devices are used in radiology; only three had registered trials on patient outcomes.
- 2Out of 1,357 total FDA-cleared AI medical devices, just three evaluated mortality, morbidity, or readmissions.
- 3Only 2.5% were linked to prospective trials, 0.9% posted results or had peer-reviewed publications.
- 462% of studies used small, homogeneous cohorts; vulnerable populations often excluded (e.g., pregnant, pediatric, non-English speakers).
- 5Authors recommend a three-phase evidence ladder with mandatory demographic reporting and larger, prospective trials.
- 6FDA's 510(k) pathway only requires substantial equivalency, not proof of clinical benefit to patients.
Why It Matters
This report highlights a significant gap between regulatory clearance and actual clinical outcome testing for radiology AI, calling attention to the need for stronger pre- and post-market evidence requirements and greater transparency. Radiology professionals and purchasers should scrutinize the clinical validation of AI tools before adoption.
Source
AuntMinnie
Related News
•Radiology Business
Multi-Vendor AI Adoption Delivers Efficiency Gains in Private Radiology
A large-scale European study shows that adopting multiple AI tools in private radiology practices leads to significant efficiency improvements.
•Radiology Business
GE HealthCare Appoints Chief AI Officer to Lead Imaging Innovation
GE HealthCare has hired Rodolphe Katra as its new global chief AI officer to drive its AI strategy in imaging.
•Radiology Business
FDA Authorizations for Radiology AI Devices Surge 42% Since 2023
FDA-cleared radiology AI devices rose by 42% between 2023 and 2025, now totaling over 1,000 approved tools.